ELVNEnliven Therapeutics, Inc.

Nasdaq www.enliventherapeutics.com


$ 24.47 $ -0.21 (-0.85 %)    

Wednesday, 08-May-2024 15:59:06 EDT
QQQ $ 439.55 $ -0.26 (-0.06 %)
DIA $ 390.50 $ 1.74 (0.45 %)
SPY $ 517.10 $ 0.05 (0.01 %)
TLT $ 90.18 $ -0.55 (-0.61 %)
GLD $ 213.58 $ -0.63 (-0.29 %)
$ 24.49
$ 24.20
$ 0.00 x 0
$ 0.00 x 0
$ 23.89 - $ 24.52
$ 9.80 - $ 26.00
432,449
na
642.47M
$ 0.17
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-14-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 02-10-2023 12-31-2022 10-K
6 10-25-2022 09-30-2022 10-Q
7 08-03-2022 06-30-2022 10-Q
8 05-06-2022 03-31-2022 10-Q
9 03-15-2022 12-31-2021 10-K
10 11-09-2021 09-30-2021 10-Q
11 08-06-2021 06-30-2021 10-Q
12 05-11-2021 03-31-2021 10-Q
13 03-05-2021 12-31-2020 10-K
14 11-05-2020 09-30-2020 10-Q
15 08-14-2020 06-30-2020 10-Q
16 05-07-2020 03-31-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 enliven-therapeutics-shares-first-look-at-safety-clinical-activity-of-lead-program

Enliven Therapeutics' Phase 1 trial results for ELVN-001 in chronic myeloid leukemia (CML) patients. Explore the promising ...

 why-fastenal-shares-are-trading-lower-by-around-7-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter f...

 enliven-therapeutics-alpine-immune-sciences-janux-therapeutics-and-other-big-stocks-moving-higher-on-thursday

U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NA...

 enliven-therapeutics-announces-proof-of-concept-data-from-phase-1-clinical-trial-of-elvn-001-in-chronic-myeloid-leukemia

Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to prec...

 enliven-therapeutics-well-positioned-with-conservative-trading-levels-analyst-says

Mizuho Securities initiates coverage on Enliven Therapeutics. Expectations high for late 2024 Phase 1 results. Enliven poised t...

 mizuho-initiates-coverage-on-enliven-therapeutics-with-buy-rating-announces-price-target-of-34

Mizuho analyst Salim Syed initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Buy rating and announces Price Tar...

 enliven-therapeutics-to-share-initial-proof-of-concept-data-from-phase-1-clinical-trial-of-elvn-001-and-host-virtual-key-opinion-leader-event-on-april-11-2024

Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the d...

 why-peraso-shares-are-trading-lower-by-over-23-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected four...

 national-cinemedia-reports-upbeat-results-joins-nordstrom-core--main-and-other-big-stocks-moving-higher-on-tuesday

U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday.

 enliven-therapeutics-announces-90m-private-placement-financing-provides-pipeline-updates

Financing includes participation from new and existing investorsNet proceeds, along with existing cash, cash equivalents and ma...

 enliven-therapeutics-q4-eps-047-beats-054-estimate

Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of ...

 enliven-therapeutics-q3-eps-051-misses-047-estimate

Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate o...

 stocks-that-hit-52-week-lows-on-monday

  During Monday's session, 201 stocks hit new 52-week lows.

 stocks-that-hit-52-week-lows-on-wednesday

  During Wednesday's session, 212 companies made new 52-week lows.

 enliven-therapeutics-q1-eps-080-misses-063-estimate

Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate o...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION